Frederick L. Locke, MD

Frederick L. Locke, MD, is chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy, and a medical oncologist and translational researcher who treats lymphoma and multiple myeloma at Moffitt Cancer Center in Tampa, Florida. He also conducts clinical trials of CAR T-cell therapy for patients with lymphoma and myeloma.

Articles by Frederick L. Locke, MD

Fred Locke, MD, Moffitt Cancer Center and Research Institute

MRD Status Guides Consolidation With Cema-Cel in ALPHA3 Trial: Fred Locke, MD

ByMaggie L. Shaw,Frederick L. Locke, MD

May 20th 2025

The ALPHA3 trial is exploring cemacabtagene ansegedleucel's (cema-cel) potential to enhance outcomes in patients who have relapsed/refractory large B-cell lymphoma, particularly those positive for minimal residual disease.

Cema-Cel Data Highlight Potential in Allogeneic CAR T: Fred Locke, MD

ByMaggie L. Shaw,Frederick L. Locke, MD

April 21st 2025

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design of the ALPHA and ALPHA2 trials, which are investigating the chimeric antigen receptor T-cell therapy (CAR T) cemacabtagene ansegedleucel (cema-cel) in relapsed/refractory large B-cell lymphoma.

Frederick L. Locke, MD, Moffitt Cancer Center and Research Institute

Gene Editing for Safer CAR T-Cell Therapy in Large B-Cell Lymphoma

ByMaggie L. Shaw,Frederick L. Locke, MD

March 17th 2025

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma.

Overcoming Delays in CAR T for Large B-Cell Lymphoma

ByMaggie L. Shaw,Frederick L. Locke, MD

March 7th 2025

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen receptor (CAR) T-cell therapy, specifically allogeneic, which uses healthy donor cells.

Allogeneic vs Autologous CAR T-Cell Therapy Explained

ByMaggie L. Shaw,Frederick L. Locke, MD

February 24th 2025

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy produced durable responses in relapsed/refractory large B-cell lymphoma.